ANDRONOVA, Tatyana Mikhaylovna,АНДРОНОВА, Татьяна Михайловна,YAKUBOVSKAYA, Raisa Ivanovna,ЯКУБОВСКАЯ, Раиса Ивановна,NEMTSOVA, Elena Romanovna,НЕМЦОВА, Елена Романовна,NESTEROVA, Evgeniya Ivanovna,НЕС
申请号：
RURU2015/000809
公开号：
WO2016/167682A1
申请日:
2015.11.23
申请国别(地区):
WO
年份:
2016
代理人:
摘要：
The invention relates to medicine, and more particularly to the treatment of patients suffering from malignant tumours, using a combination of cytostatic therapy and biotherapy. Claimed is a method of treating malignant haematological diseases or melanoma in a subject by administering one or several cytostatic drugs, which act on DNA, in combination with N-acetyl-D-glucosaminyl-(1-4)-N-acetylmuramyl-L-alanyl-D-glutamic acid (GMDP-A) according to the following treatment regimen: intravenous administration of from 1/4 to 1/2 of the standard therapeutic dose of a cytostatic drug for a given type of subject then, following administration of the cytostatic drug, a first administration of N-acetyl-D-glucosaminyl-(1-4)-N-acetylmuramyl-L-alanyl-D-glutamic acid (GMDP-A) in an effective amount and repeat administrations of GMDP-A in an effective amount established for the selected subjects. The technical result of the proposed invention for increasing the efficacy of treatment of malignant haematological diseases or melanoma is that of a synergetic effect, achieved through the combined action of a cytostatic drug and an immune response modifier thereof, which makes it possible to reduce the therapeutic dose of highly toxic cytostatic drugs without reducing their antitumour efficacy.Linvention concerne la médecine et notamment le traitement de malades présentant des tumeurs malignes par une combinaison de thérapie cytostatique et de biothérapie. La méthode de traitement des maladies hématologiques malignes ou du mélanome chez un sujet par lutilisation dun ou plusieurs cytostatiques agissant sur lADN en combinaison avec un acide N-acétyl-D-glucosaminyl-(1-4)-N-acétylmuramyl-L-alanyl-D-glutamique (GMDP-A) selon le schéma de traitement suivant des sujets : - injection intraveineuse de 1/4 à 1/2 de dose standard thérapeutique de cytostatique admise pour ce type de sujets - faire suivre linjection de cytostatique par une première injection dacide N-acétyl-D-glucosaminyl-(1-4)-N-acé
